ArticleBMC cancer2026
Comprehensive pan-cancer analysis and experimental verification of the roles of SCP2 in colon adenocarcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundSterol carrier protein 2 (SCP2) plays a critical role in intracellular lipid transport and metabolism across human tissues. The objective of this study was to perform a comprehensive pan-cancer analysis of SCP2, evaluating its expression, prognostic significance, and functional mechanisms.
methodsWe analyzed SCP2 expression using data from TCGA and GTEx databases. Prognostic significance was evaluated via Kaplan-Meier and Cox regression analyses, alongside nomogram construction. Functional mechanisms were investigated through GO, KEGG, and GSEA enrichment analyses. Genetic alterations, DNA methylation, single-cell functions, and immune infiltration were assessed using multiple bioinformatic platforms. The effects of SCP2 on cancer cell proliferation, migration, apoptosis, and sensitivity to ferroptosis were verified by in vitro experiments.
resultsSCP2 was differentially expressed in multiple tumors and correlated with clinical outcomes and immune infiltration. Enrichment analyses linked SCP2 to lipid metabolism-related pathways. In colon adenocarcinoma (COAD), SCP2 was downregulated and functioned as a tumor suppressor, as its overexpression inhibited proliferation and migration, promoted apoptosis, and strongly enhanced ferroptosis sensitivity in colon cancer cells.
conclusionOur pan-cancer analysis highlights the broad biological and clinical significance of SCP2. It functions as a tumor suppressor and key regulator of ferroptosis in COAD, highlighting its potential as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.